Alkem Laboratories Limited (ALKEM.BO)
INR 4835.45
(2.88%)
INR 4835.45
(2.88%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 17.95 Billion INR | 82.47% |
| 2022 | 9.84 Billion INR | -40.19% |
| 2021 | 16.45 Billion INR | 3.82% |
| 2020 | 15.85 Billion INR | 40.63% |
| 2019 | 11.27 Billion INR | 48.2% |
| 2018 | 7.6 Billion INR | 20.54% |
| 2017 | 6.3 Billion INR | -29.27% |
| 2016 | 8.92 Billion INR | 32.52% |
| 2015 | 6.73 Billion INR | 71.89% |
| 2014 | 3.91 Billion INR | -11.82% |
| 2013 | 4.44 Billion INR | -10.49% |
| 2012 | 4.96 Billion INR | 16.6% |
| 2011 | 4.25 Billion INR | 28.9% |
| 2010 | 3.3 Billion INR | 40.43% |
| 2009 | 2.35 Billion INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 5.45 Billion INR | 85.71% |
| 2023 Q1 | 2.86 Billion INR | 303.96% |
| 2023 FY | 17.95 Billion INR | 82.47% |
| 2023 Q3 | 5.94 Billion INR | -4.12% |
| 2023 Q4 | 2.93 Billion INR | -50.66% |
| 2023 Q2 | 6.2 Billion INR | 116.41% |
| 2022 Q2 | 3.3 Billion INR | 159.2% |
| 2022 Q4 | 709.8 Million INR | -84.39% |
| 2022 FY | 9.84 Billion INR | -40.19% |
| 2022 Q1 | 1.27 Billion INR | 18.65% |
| 2022 Q3 | 4.54 Billion INR | 37.44% |
| 2021 FY | 16.45 Billion INR | 3.82% |
| 2021 Q4 | 1.07 Billion INR | -79.53% |
| 2021 Q3 | 5.25 Billion INR | -3.42% |
| 2021 Q1 | 4.68 Billion INR | 95.06% |
| 2021 Q2 | 5.44 Billion INR | 16.27% |
| 2020 Q3 | 4.5 Billion INR | -4.47% |
| 2020 Q2 | 4.72 Billion INR | 11.86% |
| 2020 Q1 | 4.22 Billion INR | 123.56% |
| 2020 FY | 15.85 Billion INR | 40.63% |
| 2020 Q4 | 2.39 Billion INR | -46.78% |
| 2019 FY | 11.27 Billion INR | 48.2% |
| 2019 Q3 | 3.81 Billion INR | 3.0% |
| 2019 Q2 | 3.7 Billion INR | 99.95% |
| 2019 Q1 | 1.85 Billion INR | 10.82% |
| 2019 Q4 | 1.88 Billion INR | -50.58% |
| 2018 FY | 7.6 Billion INR | 20.54% |
| 2018 Q4 | 1.67 Billion INR | -17.37% |
| 2018 Q3 | 2.02 Billion INR | -20.41% |
| 2018 Q2 | 2.54 Billion INR | 86.9% |
| 2018 Q1 | 1.36 Billion INR | 102.97% |
| 2017 Q4 | 670.8 Million INR | -60.92% |
| 2017 FY | 6.3 Billion INR | -29.27% |
| 2017 Q1 | 715.6 Million INR | -47.77% |
| 2017 Q2 | 3.2 Billion INR | 348.1% |
| 2017 Q3 | 1.71 Billion INR | -46.47% |
| 2016 FY | 8.92 Billion INR | 32.52% |
| 2016 Q3 | 2.33 Billion INR | -17.48% |
| 2016 Q4 | 1.37 Billion INR | -41.3% |
| 2016 Q1 | 2.38 Billion INR | 175.48% |
| 2016 Q2 | 2.82 Billion INR | 18.44% |
| 2015 Q1 | 2.01 Billion INR | 52.92% |
| 2015 Q2 | 2.66 Billion INR | 32.73% |
| 2015 FY | 6.73 Billion INR | 71.89% |
| 2015 Q4 | 866.8 Million INR | -54.12% |
| 2015 Q3 | 1.88 Billion INR | -29.22% |
| 2014 Q1 | 855.85 Million INR | 0.0% |
| 2014 FY | 3.91 Billion INR | -11.82% |
| 2014 Q4 | 1.31 Billion INR | -18.56% |
| 2014 Q2 | 855.85 Million INR | 0.0% |
| 2014 Q3 | 1.61 Billion INR | 88.68% |
| 2013 FY | 4.44 Billion INR | -10.49% |
| 2012 FY | 4.96 Billion INR | 16.6% |
| 2011 FY | 4.25 Billion INR | 28.9% |
| 2010 FY | 3.3 Billion INR | 40.43% |
| 2009 FY | 2.35 Billion INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | -191.606% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 43.404% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | -281.358% |
| Granules India Limited | 4.05 Billion INR | -343.061% |
| Indoco Remedies Limited | 984.6 Million INR | -1723.856% |
| Achyut Healthcare Limited | 5.73 Million INR | -313188.555% |
| Ajanta Pharma Limited | 8.16 Billion INR | -120.024% |
| Alpa Laboratories Limited | 167.76 Million INR | -10604.08% |
| Brooks Laboratories Limited | -195.91 Million INR | 9265.88% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | -1011.863% |
| Bajaj HealthCare Limited | -837.93 Million INR | 2243.1% |
| Bliss GVS Pharma Limited | 754.54 Million INR | -2279.95% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 67.751% |
| Eris Lifesciences Limited | 3.91 Billion INR | -358.124% |
| FDC Limited | 3.05 Billion INR | -488.346% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 219.585% |
| Gufic Biosciences Limited | 861.35 Million INR | -1984.817% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | -326.588% |
| Ipca Laboratories Limited | 5.47 Billion INR | -228.084% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -7894.346% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 9202.461% |
| Lasa Supergenerics Limited | -217.3 Million INR | 8363.785% |
| Laurus Labs Limited | 1.6 Billion INR | -1018.511% |
| Lupin Limited | 19.14 Billion INR | 6.201% |
| Mankind Pharma Limited | 19.12 Billion INR | 6.123% |
| Medicamen Biotech Limited | 109.31 Million INR | -16328.232% |
| Medico Remedies Limited | 82.9 Million INR | -21559.53% |
| Megasoft Limited | -127.46 Million INR | 14188.227% |
| NATCO Pharma Limited | 13.88 Billion INR | -29.35% |
| Piramal Pharma Limited | 178.2 Million INR | -9977.273% |
| RPG Life Sciences Limited | 876.6 Million INR | -1948.563% |
| Sigachi Industries Limited | 571.8 Million INR | -3040.545% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 81.248% |
| Suven Pharmaceuticals Limited | 3 Billion INR | -498.031% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -6993.924% |
| Unichem Laboratories Limited | -704.74 Million INR | 2648.12% |
| Wanbury Limited | 559.56 Million INR | -3109.236% |
| Windlas Biotech Limited | 581.87 Million INR | -2986.205% |
| ZIM Laboratories Limited | 172.46 Million INR | -10312.434% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 53.471% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 563.767% |
| Divi's Laboratories Limited | 16 Billion INR | -12.236% |
| Hester Biosciences Limited | 188.89 Million INR | -9406.962% |
| Procter & Gamble Health Limited | 2 Billion INR | -793.507% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -3893.031% |
| Bal Pharma Limited | 73.92 Million INR | -24192.768% |
| Strides Pharma Science Limited | -706.14 Million INR | 2643.079% |
| Venus Remedies Limited | 284.9 Million INR | -6202.982% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | -727.918% |
| Nectar Lifesciences Limited | 49.95 Million INR | -35851.351% |
| Shilpa Medicare Limited | 318.74 Million INR | -5533.93% |
| Aarti Drugs Limited | 1.71 Billion INR | -947.596% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | -1235.84% |
| Suven Life Sciences Limited | -1.05 Billion INR | 1809.015% |
| Ind-Swift Limited | 142.31 Million INR | -12518.454% |
| Valiant Laboratories Limited | 3.19 Million INR | -561780.476% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | -224.951% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 416.497% |
| Themis Medicare Limited | 435.23 Million INR | -4025.949% |
| Hikal Limited | 696.02 Million INR | -2480.055% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | -8.415% |
| Sequent Scientific Limited | -358.69 Million INR | 5106.468% |
| Novartis India Limited | 851.9 Million INR | -2007.959% |
| Wockhardt Limited | -4.63 Billion INR | 487.855% |
| Jubilant Pharmova Limited | 771 Million INR | -2229.144% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -253110.66% |
| Neuland Laboratories Limited | 3 Billion INR | -498.433% |
| Morepen Laboratories Limited | 961.59 Million INR | -1767.483% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -12198.615% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 19895.297% |